Posted on 28/05/2009 in Pharmaceutical Company Product News Pfizer's Sutent (sunitinib malate) should lead to a higher survival rate in some cancer patients, it has been suggested.
This comment came from the National Institute for Health and Clinical Excellence (NICE) after it recommended the drug be used as a second-line treatment for those with gastrointestinal stromal tumours (GIST).
Previously, the independent organisation published guidelines suggesting the medication should be administered to patients with advanced kidney cancer as a first-line therapy.
Dr Mace Rothenberg is the senior vice-president of clinical development and medical affairs at Pfizer's oncology business department.
He noted the decision will give hope to patients affected by the disease who have developed a resistance to imatinib.
"Insights into the causative pathways involved with cancers like GIST will help us bring Sutent to the right patient at the right time," Dr Rothenberg remarked.
Final guidance is expected to be published by NICE in July.
Earlier this month, Pfizer announced it had strengthened its position in emerging markets by entering into licensing agreements with two Indian-based pharmaceutical companies.
It said the move would also significantly expand its portfolio of medicines.Other news stories from 28/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
